Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for Injection and concentrated injection
Indication
For the treatment of hepatocellular carcinoma (HCC)
Therapeutic area
Oncology